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Allurologicalstandardsofcarearebasedonthepastdeﬁnitionoftheclinicalimportanceofmacroscopichematuria.Theaimofthe
studywastoassessthephenomenonofiatrogenichematuriaincurrentclinicalpracticeandanalyzeitsoriginsinpatientsreceiving
anticoagulant drugs. Retrospective analysis of clinical documentation of 238 patients that were consulted for hematuria in 2007–
2009 by 5 consultant urologists was performed. In the group of 238 patients with hematuria, 155 (65%) received anticoagulants.
Abnormalities of urinary tract were found in 45 (19%) patients. Estimated cost of a single neoplasm detection reached the value of
3252 Euro (mean 3-day hospitalization). The strong correlation between the presence of hematuria and anticoagulant treatment
was observed. Authors suggest to redeﬁne the present and future role of hematuria from a standard manifestation of serious
urological disease to a common result of a long-term anticoagulant therapy.
1.Introduction
Hematuria, deﬁned as a clearly visible change in urine color
due to blood additives, may be a symptom of serious urinary
tract disease. Thus, it should always be an urgent diagnostic
matter for a clinician. The usage of anticoagulant or anti-
platelet drugs is beneﬁcial for patients with several diseases.
However, serious complications may appear during such a
therapy, including mucosal bleeding in the form of hema-
turia. Iatrogenic hematuria may be the reason for urological
consultation and hospitalization in urological department,
duringwhichstandarddiagnosticproceduresareusuallyper-
formed.
All urological standards of care are based on the past def-
inition of the clinical importance of presence of micro- and
macroscopic hematuria. The growing number of iatrogenic
hematuria reported in literature requires veriﬁcation of
guidelines for the management of patients with hematuria
receivinganyanticoagulanttherapy.Theaimofthestudywas
to assess the phenomenon of iatrogenic hematuria in current
clinical practice and analyze its origins in patients receiving
anticoagulant drugs. The economic aspects of diagnosing
hematuria were of special interest.
2.MaterialandMethods
Retrospective analysis of clinical documentation of 238 pa-
tients (132 men, 106 women) aged 18–99 years (average 57
years) was performed. All patients were consulted for hema-
turiain2007–2009by5consultanturologistsinthefollowing
departments: Nephrology (43), Cardiology (27), General
(23) and Vascular Surgery (11), Cardiosurgery (40), Hema-
tology (34), Gynecology (11), and Internal Diseases (49). In
the group of 238 patients with hematuria, there was a divi-
sion on the subgroup of 155 (65%) individuals, who received
anticoagulant drugs—group A (Figure 1): oral anticoagu-
lants(36%),nonfractionizedorfractionizedheparins(27%),
and antiplatelet drugs: acetylsalicylic acid (21%), clopido-
grel (11%), and ticlopidine (5%). Another 83 (35%) sub-
grouped patients, who presented with hematuria—group
B, did not receive any anticoagulant drugs. Hematuria was
found predominantly in patients over 65 years (67%), with2 ISRN Urology
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Figure 1: Individuals that received anticoagulant drugs—group A.
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Figure 2: Hematuria as the top reason for urological consultation:
the existence in group A versus group B.
concomitant diseases (71%): hypertension, coronary heart
disease, arrhythmia, and end-stage renal disease. The ma-
jority of patients had the full diagnostic panel performed
(n = 216, 91%) including USG of urinary tracts, urography
or contrast CT, and cystoscopy. The diagnostic results were
analyzed with the special attention to the negative ones,
in which no abnormalities in urinary tracts were found
(n = 209, 88%). Statistical analysis was performed using chi-
square test with Yates correction.
3. Results
Hematuria was the top reason for urological consultation
(238/871, 27%). It occurred predominantly in individuals on
anticoagulant drugs representing group A (65% versus 35%)
(Figure 2). The diagnostic panel of greatest clinical impor-
tance was ultrasound examination and cystoscopy. Abnor-
malities of urinary tract were found in overall (group A
B
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Figure 3: Abnormalities of urinary tract that were found in overall
(group A plus group B).
plus group B) in 45 (19%) patients (Figure 3): neoplasms—
bladder cancer (8), prostate cancer (6), renal cancer (4), and
urothelial cancer of upper urinary tract (3); inﬂammatory
conditions (5); benign prostate hyperplasia (12); urolithiasis
(7).ThenumberofpathologiesdetectedinthegroupAcom-
pared with group B was 8% and 16%, respectively (P = 0.2).
ThecommonprobabilityforA+Bgroupsofﬁndingatumor
was low (P1 = 0.1 in men, P2 = 0.06 in women) with the
highest one for diagnosing bladder cancer (P3 = 0.037 in
men, P4 = 0.02 in women). The estimated cost of diag-
nostic procedures for hematuria per patient was 287 Euro,
assuming average time of diagnostics as a 3-day hospitaliza-
tion (1EUR = 4.5 PLN). The cost-eﬀectiveness analysis
(number of patients × cost of a single diagnostic panel/num-
ber of neoplasms detected) revealed that the cost of a single
neoplasm detection reaches the value of 3252 Euro, which
remains unacceptable for any health provider worldwide
taking into consideration a predominant number of cases of
iatrogenic hematuria (Table 1).
4. Discussion
Anticoagulants are increasingly used for the prevention and
treatment of thromboembolic complications of vascular
diseases [1]. Bleeding from the urinary tracts is naturally one
of the most important complications of such a therapy.
Hematuria occurred to be the main reason for consulta-
tions in our material, being the matter of urological visits in
various departments in 27% of cases. Hematuria is claimedISRN Urology 3
Table 1: Costs per patient according to National Health Fund.
Payer USG of urinary tracts CT of abdominal cavity and pelvis Cytoscopy Urography
National Heath Fund (NFZ) 9,3 EUR 66,67 EUR 158,67 EUR 52,4 EUR
Overall (3-day hospitalization) 287 EUR
to involve 4% to 20% of all urological visits [2]. Those ﬁnd-
ings diﬀer slightly, but our patients made up a speciﬁc group
of great anticoagulants uptake due to serious health condi-
tions (cardiology, cardiosurgery, and vascular surgery). He-
maturia in a review of observational studies, average annual
rates of fatal, and major and major/minor bleeding was 0,8,
4,9, and 15%, respectively [3]. Gross hematuria occurred in
2,5% of the population [4]. However, the rate was higher in
the older patients and when the indication for anticoagulant
treatment was arterial disease [5]. About one-third of pa-
tients, who had bleeding complications, had more than
one indication for anticoagulants, for example, peripheral
and/or cerebral arterial disease, ischaemic heart disease, atr-
ial ﬁbrillation, and venous thromboembolic disease [5]. It is
consistent with the results obtained in our study, in which in
the majority of cases patients over 65 years were consulted,
while the main reason for anticoagulants use was heart
diseases. One should realize that especially in such a group
the anticoagulant therapy needs to be administered not only
carefully but also individually.
Bladder cancer was the most common oncological prob-
lem diagnosed in the presented study. Carcinoma, urolithia-
sis,benignprostatichyperplasia(BPH),andinﬂammatoryor
infectious etiologies are most commonly identiﬁed [6–10].
Eventhoughoneshouldthinkofbladdercancerﬁrstlyincase
of hematuria, the symptom itself is present predominantly
in patients on anticoagulants. Lower tract bleeding occurs in
57% of cases, with the majority of these being gross hema-
turia, while upper tract bleeding occurs in 40% of the cases,
with twice as much gross as microscopic hematuria [11].
Previously published studies demonstrated that gross and
microscopichematuriainlate1960sweredocumentedin4to
24% and 40%, respectively, of the patients on anticoagulant
therapy with warfarin or heparin [12–14]. It was consistent
with further studies from the 1990s, which revealed that
gross hematuria occurred in 2% to 24% of patients receiving
chronic anticoagulation with warfarin and/or aspirin for
various indications [11, 15, 16]. Furthermore, it was aspirin
that was in the majority of cases the reason of iatrogenic
hematuria (78% versus 62% in the warfarin group) [16].
Several randomized controlled trials, which enrolled 15406
patients receiving heparins, revealed that the complication
of hematuria was present in 1,6% of cases [17–23]. In the
group treated with a high dose of LMW heparin, 5,8% of
patients developed hematuria, while in the group treated
with a low dose of LMW heparin, 0,4%. Furthermore, 4,7%
of patients receiving a high dose of LDU heparin presented
with hematuria versus 0,2% of patients receiving a low dose
of LDU heparin. The incidence of hematuria in patients
treated with ﬁbrinolytic agents approached 20 to 30% [24].
The overall percentage of individuals on anticoagulants in
the consulted patients was higher in our material due to the
several reasons. First of all, the patients were enrolled in our
study from the departments, in which admitted patients are
in great need of such a therapy. Furthermore, the studies
published so far are often based on the material from general
population lacking urological point of view focused on the
possibility of a tumor presence in urinary tracts.
Urologists are often asked to evaluate the need of diag-
nostics in patients with hematuria, who are on anticoagulant
therapy. The commonly accepted diagnostic standard is
based on clinical assessment, ultrasonography and/or excre-
tory urography (IVP), and cystoscopy. During imaging and
urological procedures, an etiology is found in 17 to 82% of
cases [6–10]. In our study, only 19% of consultations proved
to be of urological matter, and that fact supports strongly the
opinion according to which the probability of ﬁnding a tum-
or in the group of patients on anticoagulants is very low. Ap-
proximately 2% to 5% of patients with microscopic hema-
turia and 10% of patients with gross hematuria have uro-
thelial carcinoma [25, 26]. In a study of 1340 healthy men
screenedforhematuria,therewasnocorrelationbetweenthe
quantity of hematuria and urological disease severity [27].
Furthermore, hematuria produced by cancer and other seri-
ous diseases was frequently intermittent and appeared in
small number of cases. In addition to that, the statistics
change drastically along with enlarging the group of patients
enrolled in the study and focusing on the conditions
that individuals were treated from. In the large study of
1930 patients, nondiagnostic hematuria was found in the
following:microscopic—68%andmacroscopichematuria—
52%,respectively[28].Asmentionedabove,thesearearterial
diseases, which due to the great need of anticoagulant
therapyforpatientssuﬀeringfromthoseconditionsandhigh
prevalence of them in the population, coexist with iatrogenic
hematuria [29]. Last and foremost is the fact that statistics
in urological studies focus mainly on individuals referred by
other clinicians to urological departments due to the highly
possible urological origins of the patient’s symptoms. In our
study,wehadachancetoexaminetheproblemclosely,dueto
the fact that the patients, who were consulted, suﬀered from
diﬀerent primary diseases.
Whether the prognosis with anticoagulants-associated
hematuria is improved due to earlier detection of asymp-
tomatic genitourinary lesions is uncertain [11]. Usually, the
degree of hematuria is related to the degree of anticoagula-
tion[11],althoughitmaybetheonlymanifestationofsignif-
icant uropathological condition. Thus, some authors recom-
mendedacompleteurologicalevaluationforallpatientswith
nontraumatic anticoagulant-associated hematuria, having
emphasized that a malignancy was found in 30% of the pa-
tientsonanticoagulanttherapy[11].Thestatementthatanti-
coagulants may serve as a potentiative enhancement for the
detection of urological disease [11] seems to be quite risky4 ISRN Urology
nowadays, however. Moreover, as it was stated above, in
our study, abnormalities of urinary tracts were found less
frequently in patients receiving anticoagulants. The econo-
mic burden of investigating hematuria provokes a less inten-
sive algorithm without loss of diagnostic eﬃcacy [28]. How-
ever, some authors claimed that ultrasound in combination
with IVP was recommended for maximal diagnostic eﬃcacy
[28].Inaddition tothat,cystoscopyshoudnotbeomittedon
the basis of type of hematuria, age, or sex [28]. The Ameri-
can Urological Association recommended cystoscopy for all
adults over 40 years old with microscopic hematuria and for
those younger than 40 years with risk factors for developing
bladder cancer [30]. However, such a policy leads to invasive
procedures, for example, cystoscopy and imaging for 95%
of patients with microscopic hematuria without malignancy
detected [31] .T h e3t y p e so fh e m o r r h a g et h a tm a yo c c u ri n
and around the urinary tract are retroperitoneal, intralumi-
nal, and intrarenal [32]. Intraluminal bleeding often results
in the formation of clots with possible painful passage or
retention in the renal pelvis, which may simulate a neoplasm
[33]. On the other hand, urothelial carcinoma of the bladder
is frequently diagnosed in patients presenting with new-
onset hematuria. The authors are of the opinion that if
the hematuria is rarely the revelator of a tumor in patients
on anticoagulant therapy, a suggestion appears to limit the
standard diagnostics procedures in those patients. The new
standardwouldcompriseultrasoundexaminationofurinary
tracts and cystoscopy to rule out renal and bladder cancer,
while common DRE would be in favor of excluding BPH and
advanced prostate cancer. The main stress, however, should
be put on the cost and eﬀectiveness analysis that was perfor-
med in our study. The high costs of a single neoplasm detec-
tion in patients presenting with hematuria are caused by the
great number of cases of iatrogenic hematuria that have to be
excluded during diagnostic procedures. The alarming results
make it clear that guidelines for anticoagulant treatment
should be reconsidered.
The other element that requires consideration is the rel-
evance of the extent of anticoagulation, which is inﬂuenced
by the indication for treatment and the patient’s compliance,
dietary status, and concomitant drug therapy [16]. Some
authors claimed that the incidence of bleeding episodes is
directly correlated to the PT [3, 7, 34]. Moreover, the inci-
denceofgrosshematuriacorrelateswiththedegreeofantico-
agulation [16]. In those studies, it was again emphasized that
despite the undeniable eﬀect of anticoagulants on iatrogenic
hematuria occurrence, each case of hematuria deserved a full
attentionofaurologist.Authorsclaim,however,thattheonly
way to reduce the number of iatrogenic hematuria, which
is diagnostic matter at urological wards, is to address that
message to the clinicians of other ﬁelds, who prescribe anti-
coagulants for their patients.
5. Conclusions
In our study, the strong correlation between the presence of
hematuriaandanticoagulanttreatmentwasobserved.Urolo-
gical origins of hematuria are more often present in patients
not receiving anticoagulant drugs. Standard urological diag-
nostic procedure, as an expensive and invasive action, should
be engaged only after critical analysis of inﬂuence of anticoa-
gulant drugs on the presence of hematuria. Authors suggest
to redeﬁne the present and future role of hematuria from
a standard manifestation of serious urological disease to a
common result of a long-term or high-dose anticoagulant
therapy. The controversy that remains is how to perform dif-
ferential diagnosis between “tumor-induced” hematuria and
“postmedication” hematuria. Further studies on this topic
would be beneﬁcial for clinicians and health care providers.
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